Prospera Private Wealth LLC Buys Shares of 502 Solventum Co. (NYSE:SOLV)

Prospera Private Wealth LLC purchased a new position in shares of Solventum Co. (NYSE:SOLV) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 502 shares of the company’s stock, valued at approximately $35,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in SOLV. Copeland Capital Management LLC purchased a new position in Solventum during the 3rd quarter worth $26,000. Mather Group LLC. purchased a new stake in shares of Solventum during the third quarter worth about $27,000. EverSource Wealth Advisors LLC purchased a new stake in shares of Solventum during the first quarter worth about $30,000. Hollencrest Capital Management acquired a new position in shares of Solventum during the second quarter valued at about $25,000. Finally, Deseret Mutual Benefit Administrators purchased a new position in shares of Solventum in the 2nd quarter valued at approximately $25,000.

Solventum Trading Up 1.7 %

Shares of SOLV opened at $70.81 on Friday. Solventum Co. has a 52 week low of $47.16 and a 52 week high of $96.05. The stock’s 50-day moving average price is $70.53 and its 200-day moving average price is $62.35. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15.

Analyst Ratings Changes

A number of brokerages have issued reports on SOLV. Wolfe Research started coverage on shares of Solventum in a research note on Thursday, September 26th. They set a “peer perform” rating on the stock. BTIG Research started coverage on Solventum in a research note on Thursday, September 5th. They issued a “neutral” rating for the company. Stifel Nicolaus assumed coverage on Solventum in a research note on Tuesday, October 8th. They set a “buy” rating and a $82.00 price target on the stock. Piper Sandler increased their price objective on Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a report on Friday, November 8th. Finally, The Goldman Sachs Group lifted their target price on Solventum from $48.00 to $54.00 and gave the stock a “sell” rating in a report on Monday, August 12th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $68.00.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.